Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Osteoporosis Reports
Erschienen in: Current Osteoporosis Reports 3/2010

01.09.2010

Bone Densitometry and Vertebral Fracture Assessment

verfasst von: E. Michael Lewiecki

Erschienen in: Current Osteoporosis Reports | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Measurement of bone mineral density (BMD) is used to diagnose osteoporosis, assess fracture risk, and monitor response to therapy. Of the different methods for measuring BMD, dual-energy X-ray absorptiometry (DXA) is the only technology for classifying BMD according to criteria established by the World Health Organization (WHO) and the only technology that is validated for BMD input with the WHO fracture risk assessment algorithm, FRAX. Vertebral fracture assessment (VFA) by DXA provides an image of the thoracic and lumbar spine for the purpose of detecting vertebral fracture deformities. Identification of a previously unrecognized vertebral fracture may change diagnostic classification, assessment of fracture risk, and treatment decisions. In comparison with standard radiographs of the spine, the correlation for detecting moderate and severe vertebral fractures is good, with a smaller dose of ionizing irradiation, greater patient convenience, and lower cost. Optimal performance of DXA and VFA requires training and adherence to quality standards.
Literatur
1.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785–795.CrossRef
2.
• Kanis JA, on behalf of the World Health Organization Scientific Group: Assessment of Osteoporosis at the Primary Health-Care Level. Technical Report. Geneva, Switzerland: World Health Organization; 2007. This is a well-referenced detailed review of the rationale and methods for developing FRAX, the WHO computer-based fracture risk algorithm.
3.
• World Health Organization: FRAX WHO Fracture Risk Assessment Tool. Available at http://​www.​shef.​ac.​uk/​FRAX/​. Accessed November 2009. The link to the online version of FRAX provides for input of BMD and VFA for estimation of the 10-year probability of fracture. This website is periodically updated to account for new data and the addition of new countries.
4.
•• Baim S, Binkley N, Bilezikian JP, et al.: Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008, 11:75–91. The ISCD Official Positions provide essential quality standards for the acquisition, analysis, interpretation, and reporting of BMD measurements and spine imaging with VFA.CrossRefPubMed
5.
Lewiecki EM, Laster AJ: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. J Clin Endocrinol Metab 2006, 91:4215–4222.CrossRefPubMed
6.
Albanese CV, Diessel E, Genant HK: Clinical applications of body composition measurements using DXA. J Clin Densitom 2003, 6:75–85.CrossRefPubMed
7.
Yang L, Peel N, Clowes JA, et al.: Use of DXA-based structural engineering models of the proximal femur to discriminate hip fracture. J Bone Miner Res 2009, 24:33–42.CrossRefPubMed
8.
Lotz JC, Cheal EJ, Hayes WC: Fracture prediction for the proximal femur using finite element models: Part I–Linear analysis. J Biomech Eng 1991, 113:353–360.CrossRefPubMed
9.
Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254–1259.PubMed
10.
WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva Technical Report Series 843. Geneva, Switzerland: World Health Organization; 1994.
11.
Cranney A, Tugwell P, Wells G, Guyatt G: Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002, 23:497–507.
12.
Wasnich RD, Miller PD: Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000, 85:231–236.CrossRefPubMed
13.
Mazess R, Chesnut CH III, McClung M, Genant H: Enhanced precision with dual-energy X-ray absorptiometry. Calcif Tissue Int 1992, 51:14–17.CrossRefPubMed
14.
Njeh CF, Fuerst T, Hans D, et al.: Radiation exposure in bone mineral density assessment. Appl Radiat Isot 1999, 50:215–236.CrossRefPubMed
15.
Crawford RP, Cann CE, Keaveny TM: Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography. Bone 2003, 33:744–750.CrossRefPubMed
16.
Guglielmi G, Lang TF: Quantitative computed tomography. Semin Musculoskelet Radiol 2002, 6:219–227.CrossRefPubMed
17.
Lewiecki EM, Richmond B, Miller PD: Uses and misuses of quantitative ultrasonography in managing osteoporosis. Cleve Clin J Med 2006, 73:742–752.CrossRefPubMed
18.
Cranney A, Jamal SA, Tsang JF, et al.: Low bone mineral density and fracture burden in postmenopausal women. CMAJ 2007, 177:575–580.PubMed
19.
Cummings SR, Karpf DB, Harris F, et al.: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002, 112:281–289.CrossRefPubMed
20.
Hochberg MC, Greenspan S, Wasnich RD, et al.: Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87:1586–1592.CrossRefPubMed
21.
Lewiecki EM, Watts NB: Assessing response to osteoporosis therapy. Osteoporos Int 2008, 19:1363–1368.CrossRefPubMed
22.
Black DM, Cummings SR, Karpf DB, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535–1541.CrossRefPubMed
23.
Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077–2082.CrossRefPubMed
24.
Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637–645.CrossRefPubMed
25.
Cummings SR, Palermo L, Browner W, et al.: Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000, 283:1318–1321.CrossRefPubMed
26.
Lenchik L, Watts NB: Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis. J Clin Densitom 2001, 4:1–4.CrossRefPubMed
27.
Bonnick SL: Monitoring osteoporosis therapy with bone densitometry: a vital tool or regression toward mediocrity? J Clin Endocrinol Metab 2000, 85:3493–3495.CrossRefPubMed
28.
Bell KJ, Hayen A, Macaskill P, et al.: Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ 2009, 338:b2266.CrossRefPubMed
29.
Watts NB, Lewiecki EM, Bonnick SL, et al.: Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res 2009, 24:1643–1646.CrossRefPubMed
30.
Lewiecki EM, Rudolph LA: How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis? J Bone Miner Res 2002, 17(Suppl 2):S367.
31.
32.
Bouxsein ML, Delmas PD: Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 2008, 23:1155–1167.CrossRefPubMed
33.
Watts NB, Miller PD, Kohlmeier LA, et al.: Vertebral fracture risk is reduced in women who lose femoral neck bone mineral density with teriparatide treatment. J Bone Miner Res 2009, 24:1125–1131.CrossRefPubMed
34.
Blake GM, Lewiecki EM, Kendler DL, Fogelman I: A review of strontium ranelate and its effect on DXA scans. J Clin Densitom 2007, 10:113–119.CrossRefPubMed
35.
Cooper C, O’Neill T, Silman A: The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group. Bone 1993, 14(Suppl 1):S89–S97.CrossRefPubMed
36.
Genant HK, Wu CY, Van Kuijk C, Nevitt MC: Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8:1137–1148.CrossRefPubMed
37.
Schousboe JT, DeBold CR: Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice. Osteoporos Int 2006 17:281–289.CrossRefPubMed
38.
Black DM, Arden NK, Palermo L, et al.: Prevalent vertebral deformities predict hip fractures and new vertebral fractures but not wrist fractures. J Bone Miner Res 1999, 14:821–828.CrossRefPubMed
39.
Ferrar L, Jiang G, Eastell R, Peel NF: Visual identification of vertebral fractures in osteoporosis using morphometric X-ray absorptiometry. J Bone Miner Res 2003, 18:933–938.CrossRefPubMed
40.
Van der Klift M, De Laet CE, McCloskey EV, et al.: The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res 2002, 17:1051–1056.CrossRefPubMed
41.
National Osteoporosis Foundation: Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
42.
Schousboe JT, Ensrud KE, Nyman JA, et al.: Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int 2005, 16:1883–1893.CrossRefPubMed
43.
Newman ED, Oleginski TP, Perruquet JL, Hummer JL: Vertebral fracture analysis using DXA- a clinically important and inexpensive method to improve osteoporosis risk assessment [abstract]. Arthritis Rheum 2005, 52(Suppl):S677.
44.
Kanis JA, Barton IP, Johnell O: Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 2005, 16:475–482.CrossRefPubMed
45.
Quandt SA, Thompson DE, Schneider DL, et al.: Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of −1.6 to −2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 2005, 80:343–349.CrossRefPubMed
46.
Chesnut III CH, Skag A, Christiansen C, et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241–1249.CrossRef
47.
Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441.CrossRefPubMed
48.
49.
Kanis JA, Johnell O: Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005, 16:229–238.CrossRefPubMed
50.
Lewiecki EM, Baim S, Siris ES: Osteoporosis care at risk in the United States. Osteoporos Int 2008, 19:1505–1509.CrossRefPubMed
Metadaten
Titel
Bone Densitometry and Vertebral Fracture Assessment
verfasst von
E. Michael Lewiecki
Publikationsdatum
01.09.2010
Verlag
Current Science Inc.
Erschienen in
Current Osteoporosis Reports / Ausgabe 3/2010
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-010-0018-z

Weitere Artikel der Ausgabe 3/2010

Current Osteoporosis Reports 3/2010 Zur Ausgabe

ReviewPaper

The Role of Exercise in the Treatment of Osteoporosis

Clinical Trial Report

Effect of High-Dose Once-Yearly Bolus of Oral Vitamin D on Falls and Fractures in Older Women

ReviewPaper

Assessment of Individual Fracture Risk: FRAX and Beyond

ReviewPaper

New Selective Estrogen Receptor Modulators (SERMs) in Development

ReviewPaper

Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men

ReviewPaper

Timing of Subsequent Fractures after an Initial Fracture

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Ärztliche Empathie hilft gegen Rückenschmerzen

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

16.04.2024 | Spondylitis ankylosans | Nachrichten

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

15.04.2024 | Knie-TEP | Nachrichten

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger
weitere anzeigen

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise